Recent Finacing
Recent Raise
Abdera applies its ROVEr platform to design heavy‑chain‑only antibody radiopharmaceuticals that pair engineered antibodies with alpha or beta emitters for targeted tumor delivery; lead DLL3 program in preclinical IND.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Abdera Therapeutics.
